{"abstract":"The Food and Drug Administration (FDA) is announcing a public meeting to obtain stakeholder input on the design and conduct of the postmarketing requirements (PMRs) for the class-wide extended-release/ long-acting (ER/LA) opioid analgesic drug products to further assess the serious risks of misuse, abuse, hyperalgesia, addiction, overdose, and death associated with their long-term use. FDA is seeking input on these issues from stakeholders, including patients, academia, researchers, State and other Federal regulators, health care organizations, health care providers, the pharmaceutical industry, and others from the general public.","action":"Notice of public meeting; request for comments.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2014/04/22/2014-09123.html","cfr_references":[],"citation":"79 FR 22499","comment_url":null,"comments_close_on":null,"correction_of":null,"corrections":[],"dates":"The public meeting will be held on May 19 and 20, 2014, from 8 a.m. to 5 p.m. Individuals who wish to present at the meeting must register by May 9, 2014. See section III under the SUPPLEMENTARY INFORMATION section for information on how to register to speak at the meeting.","disposition_notes":null,"docket_ids":["Docket No. FDA-2014-N-0374"],"dockets":[],"document_number":"2014-09123","effective_on":null,"end_page":22501,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2014/04/22/2014-09123.xml","html_url":"https://www.federalregister.gov/documents/2014/04/22/2014-09123/postmarketing-requirements-for-the-class-wide-extended-releaselong-acting-opioid-analgesics-public","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2014-09123?publication_date=2014-04-22","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2014-04-22/2014-09123/mods.xml","not_received_for_publication":null,"page_length":3,"page_views":{"count":811,"last_updated":"2026-10-25 04:15:05 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2014-04-22/pdf/2014-09123.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2014-09123.pdf?1398084581","publication_date":"2014-04-22","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2014/04/22/2014-09123.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2014-N-0374","supporting_documents_count":0,"docket_id":"FDA-2014-N-0374","regulation_id_number":null,"title":"Postmarketing Requirements for the Class-Wide Extended-Release/Long-Acting Opioid Analgesics; Public Meeting; Request for Comments","checked_regulationsdotgov_at":"2014-06-21T05:06:11Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":22499,"subtype":null,"title":"Postmarketing Requirements for the Class-Wide Extended-Release/Long-Acting Opioid Analgesics; Public Meeting; Request for Comments","toc_doc":"Postmarketing Requirements for the Class-Wide Extended-Release/Long-Acting Opioid Analgesics","toc_subject":"Meetings:","topics":[],"type":"Notice","volume":79}